KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AbbVie (ABBV) Tax Provisions (2016 - 2026)

AbbVie has reported Tax Provisions over the past 14 years, most recently at $853.0 million for Q4 2025.

  • Quarterly Tax Provisions rose 137.98% to $853.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 billion through Dec 2025, up 514.74% year-over-year, with the annual reading at $2.4 billion for FY2025, 514.74% up from the prior year.
  • Tax Provisions was $853.0 million for Q4 2025 at AbbVie, up from $526.0 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $853.0 million in Q4 2025 and troughed at -$2.2 billion in Q4 2024.
  • The 5-year median for Tax Provisions is $442.0 million (2022), against an average of $329.0 million.
  • Year-over-year, Tax Provisions skyrocketed 756.52% in 2021 and then tumbled 678.87% in 2024.
  • A 5-year view of Tax Provisions shows it stood at $226.0 million in 2021, then skyrocketed by 118.14% to $493.0 million in 2022, then dropped by 21.3% to $388.0 million in 2023, then tumbled by 678.87% to -$2.2 billion in 2024, then skyrocketed by 137.98% to $853.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Tax Provisions are $853.0 million (Q4 2025), $526.0 million (Q3 2025), and $613.0 million (Q2 2025).